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Human pluripotent stem cells, such as embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs),
have the unique abilities of differentiation into any cell type of the organism (pluripotency) and indefinite self-
renewal. Here, we show that the Rem2 GTPase, a suppressor of the p53 pathway, is up-regulated in hESCs and, by
loss- and gain-of-function studies, that it is a major player in the maintenance of hESC self-renewal and
pluripotency. We show that Rem2 mediates the fibroblastic growth factor 2 (FGF2) signaling pathway to maintain
proliferation of hESCs. We demonstrate that Rem2 effects are mediated by suppressing the transcriptional activity
of p53 and cyclin D1 to maintain survival of hESCs. Importantly, Rem2 does this by preventing protein
degradation during DNA damage. Given that Rem2 maintains hESCs, we also show that it is as efficient as c-Myc
by enhancing reprogramming of human somatic cells into iPSCs eightfold. Rem2 does this by accelerating the cell
cycle and protecting from apoptosis via its effects on cyclin D1 expression/localization and suppression of p53
transcription. We show that the effects of Rem2 on cyclin D1 are independent of p53 function. These results define
the cell cycle and apoptosis as a rate-limiting step during the reprogramming phenomena. Our studies highlight
the possibility of reprogramming somatic cells by imposing hESC-specific cell cycle features for making safer
iPSCs for cell therapy use.
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In recent years, the field of pluripotent human embryonic
stem cells (hESCs), including the discovery of induced
pluripotent stem cells (iPSCs), has moved rapidly in the
direction of finding a safe application for clinical use,
such as cell replacement therapy and modeling for drug
discovery. However, relatively little has been done to
advance our mechanistic insights into the properties of
self-renewing hESCs, and even less is known about the
mechanisms governing iPSC formation. A better under-
standing of the molecular mechanisms controlling plu-
ripotency and self-renewal would be essential for the
clinical translation of hESCs and iPSCs.
hESCs were first derived from the pluripotent cells of
the blastocyst inner cell mass and can be maintained in
vitro indefinitely with the addition of fibroblastic growth
factor 2 (FGF2) and other unknown factors secreted from
feeder cell layers (Thomson et al. 1998). The pluripotency
of hESCs is regulated by a set of unique transcription
factors including Oct4, Sox2, and Nanog (Chambers and
Smith 2004). It has been shown that a combination of
three or four factors of Oct4, Sox2, and KLf4, with or
without Myc, can reprogram somatic cells to generate
iPSCs (Takahashi and Yamanaka 2006; Takahashi et al.
2007). Analysis of partially reprogrammed iPSCs reveals
temporal and separable contributions of the four factors
and indicates that ectopic c-Myc acts earlier than the
pluripotency regulators (Sridharan et al. 2009). Indeed,
overexpression of Myc is known to regulate cyclin D1,
promoting cell cycle progression, although it remains
unknown if the cell cycle function of c-Myc plays a sep-
arate role to the pluripotency genes (Oct4/sox2/Klf4) in
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the reprogramming process (Daksis et al. 1994). Recently,
it has been shown that loss of p53 function can enhance
the efficiency of reprogramming, suggesting that the cell
cycle is a rate-limiting step in the reprogramming process
(Zhao et al. 2008; Hong et al. 2009; Kawamura et al. 2009;
Li et al. 2009; Utikal et al. 2009). Regulators of p53
transcriptional activity in hESC survival or the repro-
gramming process remain to be defined.
The cell cycle of mouse ESCs and, to a lesser extent,
hESCs has been well described; however, defined func-
tional data are lacking (Savatier et al. 2002; Stead et al.
2002; White and Dalton 2005). The core cell cycle reg-
ulatory machinery of ESCs—namely, Cyclins A, E, D, and
B, and their kinases CDK2, CDK4, and CDK6—are not
regulated in a cyclic fashion, with the exception of cyclin B
(Savatier et al. 2002; Stead et al. 2002). Cyclin D1 is
a unique cyclin in having a destruction box that responds
to cellular stress leading to its degradation and cell cycle
arrest (Agami and Bernards 2000). Of the core machinery,
cyclins A/E/CDK2 are regarded as constitutively on in
mouse ESCs, driving an almost nonexistent G1 phase into
S phase in which 60%–70% of ESCs are present. Conse-
quently, the rate of ESC proliferation is much faster, with
an average cycle lasting just 12 h compared with somatic
cells (White and Dalton 2005; Becker et al. 2006). A recent
study functionally demonstrated that Cyclin A regulates
pluripotency, albeit in mouse ESCs, but is redundant in
fibroblasts (Kalaszczynska et al. 2009). In addition to these
differences, many of the peripheral genes that control cell
cycle, such as p16INK4a, are thought to be inactive, result-
ing in a different regulation of cell cycle in mouse ESCs
(Faast et al. 2004). Given such differences between somatic
and pluripotent cells, little is known about the role of the
cell cycle in maintaining hESCs or iPSCs in culture. Much
less is known about control of apoptosis in hESCs or
iPSCs. Recently, the use of a Rho kinase inhibitor has
been shown to protect hESCs from apoptosis, and is now
used with in vitro culture of hESCs (Watanabe et al. 2007).
We sought to understand the role of the cell cycle and
apoptosis in hESCs and formation of iPSCs by investigat-
ing the Rem2 GTPase. Rem2 is a recently identified
member of the Rem/Rad/Gem/Kir (RGK) family of Ras-
related GTPases, which were first described as overex-
pressed in muscle cells of patients with type II diabetes
mediating signal transduction (Reynet and Kahn 1993;
Maguire et al. 1994). Recently, Rem2 was identified from
a functional genetic screen to bypass a p53-induced
senescence to immortalize somatic cells, demonstrating
a fundamental role for cell cycle control (Bierings et al.
2008). Here we hypothesize that the immortalization of
cells is a feature very similar to self-renewal of hESCs,
suggesting a role for Rem2 in self-renewal.
Results
Rem2 GTPase is expressed in hESCs, and is essential
for self-renewal and pluripotency
We found that Rem2 GTPase is highly expressed in six
independent hESC lines derived, compared with human
fibroblasts. Protein expression was found to be located
predominantly in the cell membrane; however, when
Rem2 was forced, overexpressed protein expression was
observed in the cytoplasm and nucleus as well (Fig. 1A).
We next tested the expression levels during hESC differ-
entiation and found that Rem2 is down-regulated under
general differentiation conditions (Fig. 1B). This suggests
that high levels of Rem2 expression are important for
maintaining a self-renewing undifferentiated state in
hESCs. Given this, we knocked down Rem2 in hESCs
using stably expressed shRNAs and found that loss of
Rem2 caused loss of hESC self-renewal, as evidenced in
colony-formation assays (CFAs) (Fig. 1C). With gain of
Rem2 function in hESCs, the differences compared with
controls suggested an overgrowth of colony formation,
which was overgrown deliberately to show the effect of
the Rem2 RNAi (Fig. 1C). Shorter-term CFAs also sug-
gested an increase in growth with Rem2 overexpression
(data not shown). To rule out any effects of the virus titer
or effect of the virus on the adherence of hESCs to the
culture plates following infection, we tested the virus
titer and took time-lapse photos following plating and did
not observe any significant effect (Supplemental Figs. 1, 2).
The karyotype of hESC lines following infection and pas-
saging was found to be normal (Supplemental Fig. 3).
The main molecular markers of pluripotency—such as
Oct4, Sox2, Nanog, and Klf4—in hESCs did not appear to
be affected by Rem2 knockdown or overexpression, in-
cluding c-Myc, even though the hESCs were dying (Fig.
1D). However, molecular markers of differentiation were
affected in undifferentiating in vitro conditions (Fig. 1D).
To investigate the role of Rem2 in pluripotency further,
we overexpressed Rem2 in hESCs and differentiated them
under general conditions (20% fetal calf serum [FCS] on
gelatin-coated flasks). We were unable to do the same
with loss of function of Rem2 due to the rapid loss of
hESC survival (Fig. 1E). Forced expression of Rem2 under
general differentiating conditions in vitro pushed ESC
fate toward an ectodermal lineage at the expense of me-
soderm (Fig. 1E), demonstrating that Rem2 plays a critical
role in maintaining a true pluripotent state.
In order to further describe the importance of Rem2 in
hESC biology, we tested a panel of established chemical
inhibitors known to affect signaling pathways essential
for maintenance of hESCs in vitro. We found that chem-
ical inhibition of FGF receptors caused down-regulation
of Rem2, and inhibition of the Rho pathway caused up-
regulation of Rem2 (Fig. 2A). However, inhibition of the
c-Jun N-terminal kinase (JNK) or transforming growth
factor (TGF) pathways had no effect on Rem2 expression,
suggesting a specific pathway of Rem2 regulation via FGF
or Rho pathways (Fig. 2A). To define the role of Rem2 in
these pathways further, we overexpressed Rem2 in hESCs
and were able to rescue the FGFr inhibitor effects of
slowing hESC growth as assessed by CFA (Fig. 2B). We
used a dox-regulated lentiviral vector (a kind gift of
Professor L. Naldini); the addition of DOX to cell culture
reduced expression of Rem2 in 2 d (data not shown). To
determine if FGF2 regulated Rem2 further, we added
FGF2 to the culture medium of human fibroblasts that
Edel et al.
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express relatively low levels of Rem2 and saw a 10-fold
induction of Rem2 RNA with 25 ng/mL (Fig. 2B). More-
over, we removed FGF2 from hESC culture medium and
saw a reduction of Rem2 levels over 5 d (Fig. 2B), further
supporting that FGF2 regulates Rem2 expression. We also
chose to investigate the effects of the Rho inhibitor fur-
ther, as it has been shown previously to control survival
of hESCs (Watanabe et al. 2007). Indeed, loss of Rem2
function by RNAi prevented the ability of the Rho in-
hibitor to promote survival of hESCs, suggesting that
Rem2 antagonizes Rho signaling in hESCs to control
survival (Fig. 2C). A role of Rem2 family members in
antagonizing Rho signaling has been shown before (Olson
2002). Furthermore, the effects of the Rho inhibitor were
to increase the cell cycle of hESCs grown on Matrigel
rather than protection against apoptosis, which is in
contrast to what has been reported previously (Fig. 2C;
Watanabe et al. 2007). Together, these data demonstrate
that Rem2 is overexpressed in hESCs compared with
fibroblasts, controls self-renewal as well as pluripotency
of hESCs, and is regulated by and mediates signaling
pathways essential for maintaining hESCs in vitro.
Rem2 GTPase cell cycle and apoptosis by regulating
cyclin D1 expression and localization in hESCs
We next sought to understand the mechanisms by which
Rem2 regulates hESC self-renewal using the same gain
(cDNA) and loss (RNAi) of gene function strategies de-
scribed above. We first analyzed the effects of Rem2 on
the cell cycle of hESCs because we showed previously
that Rem2 regulates the cell cycle of endothelial cells via
the p53 pathway to immortalize cells (Bierings et al.
2008). Given this, we first examined the effects of Rem2
on p14ARF in hESCs, but did not find any effect (Supple-
mental Fig. 4). This is not surprising, given that many cell
Figure 1. Rem2 GTPase is expressed in hESCs and is essential for self-renewal. (A, left panels) Real-time PCR of Rem2 andOct4 RNA
levels in hESC lines and endogenous Rem2 or ectopic Rem2 localization by immunostaining. (B, left panels) Photographs of
differentiation of hESCs into EBs using general conditions on gelatin (3100). (Right panel) Real-time PCR levels of Rem2 mRNA. (C,
left panel) CFA with gain (cDNA) and loss (RNAi) of function of Rem2 in hESCs in undifferentiating conditions. (Middle right panels)
Graphs of real-time PCR levels of Rem2 mRNA levels following treatment with two independent Rem2 RNAi hairpins or nontarget
RNAi controls and Rem2 cDNA in hESCs. (D, top graph) Graph of real-time PCR of mRNA levels of pluripotency genes with gain and
loss of function of Rem2. (Bottom graph) Graph of real-time PCR of mRNA levels of differentiation genes with loss of function of Rem2.
(E) Photos of immunohistochemical markers of the three germ layers after 20 d with general in vitro differentiation conditions of
hESCs, with or without ectopic Rem2.
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cycle pathways such as p16INK4a–cyclin D are not func-
tional in ESCs (Faast et al. 2004). In ESCs, we found that
loss of Rem2 caused a decrease of cells in S phase and an
increase in G2/M phase in a short-term experiment (Fig.
3A; Supplemental Figs. 5, 6). With long-term passaging of
the cells, we saw that, after 5–7 d, most of the RNAi-
treated cells were arrested or dead. Conversely, gain of
Rem2 function caused an increase in proliferation of
hESCs over time, demonstrating that Rem2 is necessary
and sufficient for maintaining the rapid cell cycle of
hESCs (Fig. 3A). This supports the initial observation
using CFA methodology that overexpression of Rem2
increases growth of hESCs (Fig. 1C).
To understand further how loss of Rem2 could be
regulating proliferation, we performed a real-time PCR
superarray for all cell cycle- and apoptosis-related genes.
We found that there were little significant differences of
gene expression on the coremachinery of cell cycle kinases
with loss of Rem2 in hESCs (Fig. 3A). To our surprise, the
only exception was up-regulation of cyclin D1/CDK6,
which normally promotes cell cycle progression—the
opposite of what we observed with hESCs treated with
Rem2 RNAi (Figs. 1, 3A). We show that the up-regulation
of cyclin D1 with loss of Rem2 is partially cytoplasmic in
undifferentiated conditions, and suggests that expression
of Rem2 expression regulates cyclin D1 localization to
maintain cell cycle and survival of hESCs (Fig. 3A). We
also observed a deregulation of DNA damage-controlling
genes such as BRCA2 by Rem2, which we validated by
Western blot analysis, suggesting further a role for pro-
tection of apoptosis pathways (Fig. 3A). The apparent
specific regulation of DNA damage-controlling genes by
Rem2 suggests a more specific regulation than that
known for c-Myc.
Given that loss of Rem2 caused hESC death in vitro, we
assessed apoptosis using three approaches. With all three
approaches—FACs analysis for DilC, DAPI staining, and
Western blot for cleaved caspase 3—an increase in apo-
ptosis with loss of Rem2 was observed (Fig. 3B; Supple-
mental Fig. 7). Overexpression of Rem2 did not reveal
a significant change by FACs; however, by Western blot
analysis, we observed a decrease in cleaved caspase 3 with
Rem2 cDNA in hESCs (Fig. 3B), suggesting that they were
protected from apoptosis with overexpression of Rem2
even under nonstress conditions. To test if overexpres-
sion of Rem2 protected hESCs from apoptosis, we treated
the hESCs with mitomycin C, an activator of the DNA
damage p53/apoptosis pathway. We observed that the
hESCs were protected from apoptosis with eightfoldmore
alive cells in Rem2/mitomycin C-treated hESCs com-
pared with controls (Fig. 3C). To dissect the mechanism
further,Western blot analyses showed thatMDM2 levels,
an indirect readout for the transcriptional activity of
p53, were not induced in hESC cells with ectopic Rem2
Figure 2. Rem2 is regulated and mediates FGF2/Rho signaling. (A) Graph of real-time PCR of Rem2 RNA levels in hESCs treated with
chemical inhibitors of signaling pathways known to be important in hESC survival: FGFr (SU5402), JNK (SP600125), TGF-b-R1 Kinase-
Alk5 (Inhibitor II), and Rho-kinase (Y-27632). (B, top left panel) Graph showing hESCs cultured without FGF2 in the media and Rem2
expression levels measured by real-time PCR. (Bottom left panel) Real-time PCR of Rem2 expression in human fibroblasts treated with
different concentrations of FGF2 growth factor. (Right panel) Rescue of effects of FGFr inhibitor (SU5402) by ectopic Rem2. CFA of
Rem2-overexpressing hESC growth on Matrigel with and without DOX plus FGFr inhibitor SU5402. (C, top left panel) Graph of effect
of Rho kinase inhibitor on hESC proliferation. (Bottom left panel) Graph representing FACs analysis of apoptosis using DilC in hESCs
treated with Rho inhibitor. Note that Rho inhibitor does not protect hESCs from apoptosis, but rather increases proliferation of hESCs
cultured on Matrigel. (Right panel) Rescue of Rho inhibitor effects on proliferation by Rem2 RNAi in hESCs by CFA.
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following mitomycin C treatment as compared with the
clear p53 transcriptional activation observed in the con-
trol, suggesting a role for Rem2 in suppressing p53 ac-
tivation (Fig. 3C). Moreover, MDM4 protein, which is
known to bind directly to p53 to inhibit its activity and
needs to be degraded in response to stress to allow for p53
activation, was not degraded with mitomycin C treat-
ment in Rem2 hESCs, further supporting a role for Rem2
in suppression of the p53 pathway (Fig. 3C). We show that
Rem2 prevents the ubiquitination and degradation of
MDM4 upon stress, suggesting that Rem2 is a novel and
active component in the DNA damage–ubiquitination
Figure 3. Rem2 GTPase controls cell cycle and apoptosis by regulating cyclin D1 and p53. (A, top left panel) Graph of FACs analysis of
cell cycle profile of hESCs with loss of function of Rem2. (Top right panel) Proliferation curve of hESCs with loss and gain of Rem2
function. (Middle left panel) Real-time PCR superarray of cell cycle genes (summary of most significant changes) with loss of Rem2
function compared with nontarget RNAi controls in hESCs. (Bottom left panel) Validation of array using Western blot of cyclin D1
protein levels with loss and gain of Rem2 function in hESCs. (Bottom right panel) Validation of array by Western blot of BRCA2 protein
levels with loss and gain of Rem2 function in hESCs. (Far bottom panel) Photographs of immunostaining with cyclin D1 with loss and
gain of Rem2 function in hESCs. The graph shows quantification of the percent of cells expressing high levels of cyclin D1 in the
cytoplasm. (B, top left panel) Graph of FACs analysis of apoptosis using DilC and PI staining of hESCs with loss and gain of Rem2
function. (Top middle panels) Photographs of DAPI/Rem2 immunostaining of hESCs with no infection control or with Rem2 RNAi
demonstrating apoptotic nuclei with loss of Rem2 function in undifferentiating conditions. (Top right panels) FACs histograms of
apoptosis (assessed by DilC) with and without Rem2 gain of function in hESCs treated with or without 5 mg/mL Mitomycin C. (Bottom
left panel) Western blot of activated caspase 3 levels with loss and gain of Rem2 function in hESCs. (C, top left panel) Western blot
analysis of p53 pathway with and without Rem2 gain of function in hESCs treated with or without 5 mg/mL Mitomycin C. (Top right
panel) Western blot of cyclin D1 protein localization and level of expression with and without Rem2 gain of function in hESCs treated
with or without 5 mg/mL Mitomycin C. The graph indicates quantification of the percent of hESCs with cyclin D1 protein localization.
(Middle left panel) Quantification of ubiquitination assay for MDM4 with or without Rem2 and with or without Mitomycin C
treatment demonstrates reduced ubiquitination of MDM4 with Rem2 overexpression in hESCs treated with Mitomycin C compared
with input controls (MDM4). Note: A photo of the blot can be seen in Supplemental Figure 8. (Bottom left panel) Graph of real-time
PCR of p53 transcriptional targets MDM2 and p21CIP mRNA levels treated with 5 mg/mL Mitomycin C and with or without Rem2 in
hESCs, clearly showing that Rem2 regulates the transcriptional activity of p53 under stressful conditions.
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signaling pathway in response to stress (Fig. 3C). To
further establish and define that Rem2 suppresses p53
transcriptional activity, we demonstrate that ectopic
Rem2 blocks the induction of MDM2 and p21CIP mRNA,
two transcriptional targets of p53 observed in control
cells in the presence of stress, and that a p53 luciferase
reporter construct is suppressed following treatment with
mitomycin C with ectopic Rem2 (Fig. 3C; Supplemental
Fig. 8). Although the fold activation of the p53 luciferase
reporter construct by mitomycin C in controls is small,
the obvious suppression by Rem2 in the presence of
mitomycin C below basal levels (<1) demonstrates clearly
the ability of Rem2 to suppress p53 transcriptional
activity under stress (Supplemental Fig. 8).
We observed that the FGF2 inhibitor (SU5402) inhibits
Rem2 expression and consequently increases Cyclin D1
mRNA expression levels, consistent with the Rem2
RNAi data (Fig. 3A), implicating the FGF2 pathway in
regulation of Cyclin D1 in hESCs (Supplemental Fig. 9).
Moreover, Cyclin D1 has been shown previously to be a
target of the DNA damage pathway (Agami and Bernards
2000). Given this, we also examined if Rem2 controlled
cyclin D1 protein level when hESCs were placed under
stress with mitomycin treatment. Whereas cyclin D1 nor-
mally is degraded in response to cell stress, which we
observed in hESCs byWestern blotmethodology, we show
that ectopic Rem2 protected the degradation of cyclin D1
under stress conditions in hESCs (Fig. 3C). Moreover we
observed that stress of Rem2-overexpressing hESCs causes
a nuclear localization of cyclin D1, which would enable
faster proliferation and survival (Fig. 3C). Therefore, under
normal culturing conditions of hESCs, Rem2 maintains
cyclin D1 expression and localization, whereas under
stressful conditions such as DNA damage, Rem2 main-
tains cyclin D1 nuclear to promote hESC survival. Taken
together, these data define Rem2 as a critical mediator of
proliferation and apoptosis in hESCs by suppressing the
ability of p53 to transcriptionally induce its targets, aswell
as the expression/location of cyclin D1 to promote sur-
vival and therefore self-renewal of hESCs in vitro.
Rem2 GTPase controls efficiency of reprogramming
into iPSCs
Recent work has demonstrated that ectopic Rem2 regu-
lates the p53 pathway to immortalize primary cultured
cells, indicating a possible role with instating self-
renewal-like properties in somatic cells (Bierings et al.
2008). Moreover, it has been shown that loss of p53 can
enhance reprogramming, although regulators of p53 re-
main to be defined (Zhao et al. 2008; Hong et al. 2009;
Kawamura et al. 2009; Li et al. 2009; Utikal et al. 2009).
Given that we showed that Rem2 maintains self-renewal
and pluripotency in hESCs, we next asked if Rem2 could
enhance reprogramming of somatic cells into iPSCs. To
answer these questions, we reprogrammed somatic cells
with three factors alone (Oct4/sox2/Klf4) or with either
Myc, cyclin D1, or Rem2 (Supplemental Fig. 10).
We first observed that endogenous Rem2 levels in-
crease in reprogrammed iPSCs, similar to levels of Rem2
in hESCs (Fig. 4A). We also found that cyclin D1 protein
levels were highly expressed in iPSCs compared with
ESCs (Supplemental Fig. 11). Consequently, we investi-
gated if Rem2 could increase the number of pluripotent
cells reprogramming with just three factors by staining
for the early pluripotency marker SSEA4 (Fig. 4B). The
increase in proliferation that we observed was correlated
to an eightfold increase in SSEA4-positive cells express-
ing three factors plus Rem2, which was more than that
observed from three factors plus c-Myc (Fig. 4B; Supple-
mental Fig. 12). Next, we asked if Rem2 expression is
essential for the reprogramming process by stably knock-
ing down Rem2 using a lentiviral system to deliver
shRNAi in human keratinocytes infected with four
factors—Oct4, Sox2, Klf4, and c-Myc. We achieved a
50% knockdown of Rem2 mRNA in human keratino-
cytes (data not shown), and observed a 60% loss of
alkaline phosphatase (AP)-positive-stained colonies (Fig.
4C). This demonstrates that Rem2 expression is an
essential component of the reprogramming phenomena
of somatic cells to iPSCs. The trend of an increase in
SSEA4-positive cells with three factors plus Rem2 corre-
lates to the AP staining, thus validating AP staining as
a reliable tool for assessment of reprogramming effi-
ciency. We observed no effect of Rem2 on p14ARF levels
in keratinocytes or mouse embryonic fibroblasts (MEFs),
ruling out regulation of this pathway during iPSC forma-
tion (Supplemental Fig. 4). Finally, we overexpressed
Rem2 with just three factors—Oct4, Sox2, and Klf4—to
determine if gain of Rem2 function could enhance re-
programming and replace c-Myc. We saw an eightfold
increase in efficiency of reprogramming with three fac-
tors plus Rem2, which was as efficient as using four fac-
tors (Fig. 4C,D).
To check that we had made iPSCs, we overexpressed
Rem2 with three or four factors and picked colonies for
characterization. Rem2 iPSC colonies have been named
RiPs (Rem2-induced pluripotent stem cells) and were
picked between days 12 and 18 for expansion. We
observed that RiPs were threefold more likely to survive
picking and expansion than other iPSCs, and that four
factor plus Rem2 colonies were more prone to differenti-
ation during expansion than three factors plus Rem2 (data
not shown). Further characterization of the RiPs revealed
protein expression of ESC markers OCT4, Sox2, Nanog,
Tra1-81, Tra1-60, SSEA3, and SSEA4 (Fig. 5A, panels a–l).
To determine if RiPs were able to differentiate into the
three germ layers, a hallmark of true ESC function,
embryoid bodies (EBs) were made using general differen-
tiation conditions, and we show that they were rapidly
able to form all three germ cell layers, demonstrating that
real iPSCs were made (Fig. 5B, panels m–u). Real-time
PCR analysis of the endogenous and transgene expression
of the four factors demonstrates that endogenous factors
are up-regulated in RiPs and the transgenes are almost all
totally silenced (Fig. 5C). We found consistently that the
Oct4 transgene shows some residual expression in other
studies where we made fully characterized human iPSCs
(Aasen et al. 2008). These data demonstrate that Rem2 is
able to reprogram human somatic cells into iPSCs with
Edel et al.
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just three factors and is as efficient as c-Myc in repro-
gramming.
Rem2 is dependent on p53 and regulates cyclin
D1 localization to enhance reprogramming
We gleaned from the work in hESCs that Rem2 regulates
cyclin D1 expression and localization. Cyclin D1 is amain
regulator of the cell cycle and is a target of c-Myc, sug-
gesting further that a change in the cell cycle is required
to attain pluripotency during reprogramming. We sought
then to understand if the regulation/localization of cy-
clin D1 is responsible for reprogramming human somatic
cells toward iPSCs. We overexpressed wild-type cyclin D1
and a cytoplasmic-expressed cyclin D1 mutant in an at-
tempt to mimic the effects of Rem2 on cyclin D1 reg-
ulation and localization in hESCs (Fig. 4A,B). We over-
expressed these cyclin D1 constructs with only three
factors—Oct4/sox2/Klf4—as Myc is known to regulate
cyclin D1 (Daksis et al. 1994). We found that overexpres-
sion of wild-type cyclin D1 (a target of c-Myc) increased
the efficiency of reprogramming more than threefold, by
increasing the number of cells in S phase of the cell cycle
(P = 0.009), demonstrating that cyclin D1 up-regulation is
sufficient for enhancing reprogramming (Fig. 4C,D). How-
ever, the converse was true with overexpression of the
cytoplasmic cyclin D1 mutant, which caused apoptosis,
loss of S-phase cycling cells (P = 0.05), and loss of re-
programming capacity (Fig. 4C,D). We observed in hESCs
that overexpression of Rem2 under stress conditions in
vitro protected hESCs to increase survival bymaintaining
high levels of cyclin D1 protein (Fig. 2). Because repro-
gramming is thought to evoke high levels of cellular stress,
we measured Cyclin D1 protein levels and location by
immunostaining in early reprogramming colonies (at 12 d)
that were made with three factors alone (Oct4/Sox2/Klf4)
with either Rem2 or c-Myc as well. We show that cyclin
D1 is mainly cytoplasmic, where it is inactive, when re-
programming with three factors, which may explain why
it is so inefficient compared with four factors. However,
there is a clear up-regulation of cyclin D1 protein levels
and a shift to the nucleus with three factors plus Rem2,
where it is active to phosphorylate Retinoblastoma Pro-
tein (pRb) and promote cell cycle progression (Fig. 4E). This
was also the case for three factors plus c-Myc, where most
early reprogramming cells have nuclear-located cyclin D1
expression (Fig. 4E). Next, we asked whether localization
of cyclin D1 was independent of p53, and found that, in
early developing human iPSCs (RNAi for p53) or mouse
iPSCs (using p53-null MEFs), loss of p53 did not affect the
localization of cyclin D1 by Rem2 or c-Myc, suggesting
that it is independent of p53 (Fig. 4E). Taken together, the
data demonstrate that the Rem2 control of the localization
of cyclin D1 is critical to the reprogramming phenomena.
We next asked if the role of Rem2 was independent of
the p53 pathway during reprogramming, and if their ef-
fects during reprogramming are via proliferation and/or
apoptosis pathways. We infected human keratinocytes
Figure 4. Rem2 GTPase controls efficiency of repro-
gramming into iPSCs. (A) Graph of real-time PCR of
Rem2 levels in fibroblasts compared with iPSCs and
hESCs. (B, top panel) Graph of SSEA4 staining of early
reprogramming cells (day 12) as analyzed by FACs. The
trend of an increase in SSEA4-positive cells with 3F plus
Rem2 correlates to the AP staining, thus validating AP
staining as a reliable tool for assessment of reprogram-
ming efficiency. (Bottom panel) Graph of FACs analysis
of the same cells analyzed for SSEA4 and GFP (a poly-
cistronic Oct4/Sox2/Klf4/Myc or Rem2 GFP-tagged
expression vector was used for these reprogramming
experiments) for percent of early reprogramming cells
in S phase (measured by EDU and DAPI). (C, left panel)
Photo of colony formation assay of reprogramming with
four factors with Rem2 RNAi or nontarget RNAi stained
with AP. (Right panel) Graph of quantification of num-
ber of AP-positive colonies with four factors with Rem2
RNAi or nontarget RNAi. (D, left panel) Photo of CFA of
reprogramming with three (no c-Myc) factors with Rem2
cDNA or controls stained with AP. (Right panel) Graph
of quantification of number of AP-positive colonies
with three factors with Rem2 cDNA or controls stained
with AP.
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with Rem2, with and without a p53 dominant-negative
construct (p53dd), a p53 RNAi construct we published
previously (Kawamura et al. 2009), and expression was
checked by Western blot analysis (Supplemental Fig. 12).
Infected cells were split into CFAs to assess efficiency
(on feeder layers) or into slide flasks for assessment
of apoptosis (tunnel) and proliferation (phospho-H3) of
early reprogramming colonies (day 12) by selecting only
SSEA3-positive colonies (Supplemental Fig. 11). We found
that loss of p53 with three factors increased efficiency of
reprogramming eightfold compared with three factors
alone, and this was due to reducing apoptosis and in-
creasing the number of proliferating cells, suggesting that
both the apoptotic and cell cycle functions of p53 are
critical for the reprogramming process (Fig. 4F,G). In the
absence of an active p53, overexpression of Rem2 en-
hanced reprogramming to ;10-fold; similar to three fac-
tors with p53dd alone, demonstrating that Rem2 cannot
enhance reprogramming in the absence of an active p53
(Fig. 4F,G). Overexpression of Rem2 or cyclin D1 caused
a large increase in the number of SSEA3-positive pro-
liferating cells in early reprogramming colonies, demon-
strating that control of cell cycle during reprogramming
is essential for the process (Fig. 4H). Taken together, these
data demonstrate that a cell cycle element is essential
for the early reprogramming process, and that Rem2
increases efficiency of early reprogramming events by ac-
celerating proliferation and protection of cells via its reg-
ulation of cyclin D1 localization and suppression of p53
(Fig. 4).
Discussion
In order to develop further our understanding of human
pluripotent ESCs, we investigated the role of Rem2
GTPase because it is known to regulate p53 to immortal-
ize somatic cells, a feature similar to self-renewal of both
hESCs and hiPSCs. This study identified Rem2 GTPase
as a gene highly expressed in hESCs and iPSCs com-
pared with fibroblasts to promote survival and therefore
Figure 5. Characterization of RiPs. (A, panels a–l) Phase contrast and immunostaining of iPSCs (one clone) and RiPs (two clones) for
pluripotency markers Oct4, SSEA3, Sox2, SSEA4, Tra-81, Nanog, and Tra-60. (B, panels m–u) Immunostaining of differentiation
markers following 3 wk of general differentiation of iPSC and RiP clones (gelatin with 20% FCS medium) for Alfafeto protein, Fox2A,
Sox9, Alfa smooth muscle (ASMA), and TUJ1. (C) Real-time PCR of transgenes and pluripotency marker expression in RiPs compared
with hESCs and somatic cells.
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self-renewal of hESCs in vitro. Furthermore, wemake the
novel discovery that Rem2 regulates the ability of hESCs
to differentiate into all three germ layers, suggesting a role
in pluripotency. By manipulating the expressed levels of
Rem2, we can force hESCs toward an ectodermal lineage
under general differentiating conditions. Rem2 has been
identified in neuronal developments such as control
neuron synapse formation (Paradis et al. 2007) and has
enriched expression in the central extended amygdala
(Becker et al. 2008). Recently, two microarray-based ex-
periments identified Rem2 as overexpressed in the for-
mation of two different adult stem cells: those making
pancreas, and those making dopamine neurons (Lee et al.
2006; Treff et al. 2006). Further work to define the role of
Rem2 and its cell cycle targets toward a specific cell fate
is warranted.
The control of apoptosis and cell cycle are two essential
functions for ESCs to maintain their self-renewal capac-
ity. In hESCs we show that Rem2 regulates cyclin D1
expression and p53 transcriptional activation controlling
cell cycle and apoptosis of hESCs. The regulation of DNA
damage genes such as p53 and the cell cycle kinase cyclin
D1 suggests that Rem2 is an important regulator of ap-
optosis and maintaining an ESC-like cell cycle profile.
The ability of Rem2 to regulate the localization of cyclin
D1 and to suppress p53 transcriptional activity during
stress underscores a pivotal functional role for Rem2
to maintain survival and a rapid rate of cell cycle, and
therefore self-renewal of hESCs. Indeed, assessment of
SSEA4-, SSEA3-, and TRA1-60-positive cells with three
factors (Oct4/Sox2/Klf4) plus Rem2 during reprogram-
ming reveals that Rem2 can increase the number of
pluripotent cells during the early reprogramming process
(Fig. 6H). By using either p53RNAi or p53dd cells for
reprogramming, and FACs sorting for SSEA3- or TRA1-
60-positive cells, Rem2 cannot enhance reprogramming.
This suggests that Rem2’s main mechanism of action is
via the p53 pathway (Fig. 6F,H). We also showed that
overexpression of cyclin D1, which is also a target of
c-Myc, increases the number of SSEA4-positive cells in
S phase (Fig. 4B), demonstrating for the first time that the
cell cycle functions of c-Myc plays an important role in
the efficiency of reprogramming. Taken together, the data
clearly define that the core machinery of the cell cycle—
namely, cyclin D1—is a rate-determining step in the
reprogramming phenomena. We propose that imposing
a hESC-like cell cycle profile in somatic cells with Rem2
or cyclin D1, in addition to the pluripotency module
(Oct4/Sox2/Klf4), may be a safer and more efficient way
to make iPSCs. It remains to be defined if other cell cycle
genes overlap with pluripotency or not, which future
gain- and loss-of-function studies of other cell cycle genes
would reveal.
When we stressed hESCs with a DNA-damaging agent,
we observed that cyclin D1 is degraded, as expected. With
overexpression of Rem2 in the presence of stress, cyclin
D1 is not degraded in hESCs and moves nuclear, relative
to hESCs without Rem2 but equally stressed, suggesting
that localization of cyclin D1 is critical for maintaining
self-renewal and pluripotency. Indeed, overexpression of
Rem2 during the early reprogramming stages up-regu-
lates andmaintains cyclin D1 exclusively nuclear, further
supporting that cyclin D1 localization is an important
rate-determining step during acquisition of pluripotency
(Fig. 6E). Moreover, overexpression of a mutant cyclin D1
that is cytoplasmically expressed (to mimic the effects of
loss of Rem2 on cyclin D1 in hESCs) caused an increase
in apoptosis of somatic cells and loss of reprogramming
efficiency, consistent with the idea that maintenance of
proper cyclin D1 location in human pluripotent cells is
essential for self-renewal and pluripotency. This critical
function of Rem2 to regulate Cyclin D1 under stressful
conditions (which reprogramming presents to a cell), and
to maintain it nuclear during early reprogramming, in-
creases the efficiency of reprogramming by accelerating
the cell cycle. The phosphorylation of Rb has been
described as a ground state of the hESC cell cycle profile,
suggesting that Rem2 can instate a hESC cell cycle profile
during reprogramming. The novel discovery that the
localization and overexpression of cyclin D1 controls
reprogramming defines a critical role for the cell cycle
during the reprogramming process. How Rem2 controls
cyclin D1 localization during reprogramming to achieve
pluripotency remains to be defined, although modifica-
tion of the ubiquitination and protein transport pathways
seem likely pathways involved. Rem2GTPase is a unique
GTPase in having an extended N-terminal protein tail
with many signal transduction-binding sites, and we did
not rule out the GTPase activity of Rem2 in regulating
cell survival decisions.
Indeed, the process of reprogramming is thought to
evoke huge cellular stresses caused by the introduction of
the four factors and the viral or transfection procedures
themselves. It follows then that the introduction of genes
such as Rem2 in somatic cells, which can control the
effects of cellular stresses, increases survival and there-
fore the efficiency of reprogramming. Here we show that
Rem2GTPase can enhance the reprogramming efficiency
of somatic cells into iPSCs eightfold (Fig. 4). This sup-
ports the hypothesis that loss of p53 signaling is an
important step in making reprogramming more efficient,
and suggests that signaling proteins upstream of p53 are
important contributors to reprogramming by monitoring
cellular stress levels.
In conclusion, the identification of Rem2 function in
hESCs and reprogramming will help with understanding
the molecular mechanisms of survival and proliferation
that are essential for self-renewal and pluripotency of
hESCs. Our studies highlight the possibility of repro-
gramming somatic cells by imposing hESC-specific cell
cycle features—rather than relying on oncogenes such as
c-Myc—for making safer iPSCs for cell therapy use.
Materials and methods
Culture of hESCs
hESCs were derived and fully characterized at the CMR[B] (Raya
et al. 2008). They were maintained on either human feeder layers
or on Matrigel-coated plates with HUES medium, consisting of
Rem2 controls self-renewal and reprogramming
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KO-DMEM (Invitrogen) supplemented with 10% KO-Serum
Replacement (Invitrogen), 0.5% human albumin (Grifols), 2 mM
Glutamax (Invitrogen), 50 mM 2-mercaptoethanol (Invitrogen),
nonessential amino acids (Cambrex), and 10 ng/mL bFGF
(Peprotech). Cultures were maintained at 37°C, 5% CO2, with
media changes every other day. hESCs were routinely tested
for normal karyotype. For hESC lines adapted to Matrigel-
coated plates, HUES-conditioned medium from irradiated MEFs
was used instead. MEFs were cultured using 10% FCS with
Dulbecco’s modified Eagle’s medium (DMEM).
Constructs and lentivirus production
Rem2 cDNA made from RNA extracted from hESCs was cloned
into the pCCL TET-off-inducible lenti-vector. Rem2 RNAi
constructs and nontarget RNAi controls were purchased from
Figure 6. Rem2 is dependent on p53 and regulates cyclin D1 localization to enhance reprogramming. (A) Photographs of
immunostaining with cyclin D1 in somatic cells before reprogramming, overexpressing GFP (control), cyclin D1, and cyclin D1
mutant (L32A). Magnification, 2003 . (B) Graph of the quantification of the number of somatic cells before reprogramming expressing
cyclin D1 in the cytoplasm, demonstrating that the expression of the mutant cyclin D1 is more cytoplasmic. (C) Graph summarizing
FACs analysis of the percent of cells in S phase or apoptotic cells by DilC plus PI staining for overexpressing GFP (control), cyclin D1,
and cyclin D1 mutant (L32A) in somatic cells before reprogramming, demonstrating that the mutant causes apoptosis and reduced
proliferation. P-values given by a Student’s t-test. (D) Photo of CFA of reprogramming colonies at day 21with three factors, three factors
plus cyclin D1, or three factors plus cyclin D1 mutant (L32A) stained with AP. (Insert) The number of colonies was quantified by image
analysis software and is presented as a graph, demonstrating loss of reprogramming efficiency with expression of mutant cyclin D1. (E)
Photos of localization of cyclin D1 during early reprogramming (at day 12), demonstrating a nuclear localization with ectopic Rem2 plus
three factors (Oct4/Sox2/Klf4) and three factors plus c-Myc (four factors). P53 RNAi-treated cells were also reprogrammed, and
demonstrate nuclear localization of cyclin D1. (E) Graph of quantification of percent of cells with nuclear-located cyclin D1. (F)
Assessment of Tra1-60-positive cells in early reprogramming colonies with p53 RNAi-treated cells, Rem2 and c-Myc (4F) assessed by
FACs analysis. (G) Assessment of AP-positive colonies in early reprogramming colonies with p53dd-treated cells. The number of
colonies was quantified by image analysis software and is presented as a graph. (H) Quantification of proliferation and apoptosis in early
developing reprogramming colonies with three factors (Oct4/Sox2/Klf4) plus Rem2 or cyclin D1 or p53dd at day 12 by immunostaining
for tunnel (red bars), phospho-H3 (green bars), and SSEA3 (to assess specific reprogramming colonies) for different gene treatments as
described in the figure.
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RZPD and were cloned into the pLKO.1puro lenti-vector (Sigma-
Aldrich). All lentiviruses were made using a third-generation
approach. Briefly, MDL (6.5 mg), VSV (4 mg), REV (2.5 mg), and
lentiviral constructs (10 mg) were transfected into 293T cells
using Lipofectamine2000 overnight. 293T cells (American Type
Culture Collection no. CRL-12103) were used for the production
of lentiviruses. These cell lines were grown in DMEM (GIBCO)
supplemented with 10% fetal bovine serum (FBS; Biowhitaker).
The next day, mediumwas refreshed, and the following day virus
was harvested, tested for titer using an HIV-1 p24 ELISA kit
(Perkin Elmer), and stored at !80°C in 1-mL aliquots. hESCs
(200,000) were infected in suspension with 1 mL of viral
supernatant for 1 h at 37°C and then plated in six-well Matrigel-
coated plates with a further 1 mL of conditioned media. The next
day, media was changed, cells were allowed to recover, and ex-
periments were performed. For proliferation curves, equal cells
were plated and then counted every 5 d.
Constructs and retroviral production
Cyclin D1 pBabe puro cDNA constructs were a kind gift from
Reuven Agami (Agami and Bernards 2000). cDNAs for Rem2,
Oct4, and Sox2 were amplified from ES[4] total RNA by RT–
PCR. Klf-4 was amplified from IMAGE clone 5111134. c-Myc
T58A mutant cDNA was amplified from DNA kindly provided
by Dr. Luciano DiCroce. The amplified cDNAs were cloned into
the EcoRI/ClaI sites of a modified pMSCVpuro vector, which
allows the expression of N-terminal Flag-tagged proteins. The
single polycistronic vector containing three factors (Oct4, Sox2,
and Klf4) or four factors plus a GFP tag has been described
elsewhere (Gonzalez et al. 2009). Retroviruses for the four factors
were produced independently after transfecting the cell line
Phoenix Amphotropic using Fugene 6 reagent (Roche) according
to the manufacturer’s directions. After 24 h, the DMEM was
replaced, cells were incubated at 32°C, and the viral supernatant
was harvested after 24 h and 48 h.
Generation of iPSCs
The generation of iPSCs using human primary keratinocytes has
been described before (Aasen et al. 2008). Briefly, cells were
isolated from juvenile foreskins (2–16 yr old) using dispase to
remove the dermis from the epidermis followed by trypsiniza-
tion and culture in serum-free low-calcium medium (Epilife;
Invitrogen) at 37°C, 5% CO2, 5% O2, and used between two and
four passages. For reprogramming experiments, ;50,000 or
100,000 cells were seeded per well of a six-well plate and infected
with a virus from a polycistronic vector (Oct4, Sox2, and Klf4
plus Rem2) or with a 1:1:1:1 mix of retroviral supernatants of
Flag-tagged Rem2, OCT4, SOX2, KLF4, and c-MYCT58A in the
presence of 1 mg/mL polybrene. Infection consisted of a 45-min
spinfection at 750g, washed with PBS and with keratinocyte
medium replaced. Two rounds of infections on consecutive days
were performed. Two days after beginning the last round of
infection, cells were trypsinized and seeded onto feeder layers of
irradiated MEFs in the same culture medium. The medium was
changed upon plating to hESC medium, consisting of KO-
DMEM (Invitrogen) supplemented with 10% KO-Serum Re-
placement (Invitrogen), 0.5% human albumin (Grifols), 2 mM
Glutamax (Invitrogen), 50 mM 2-mercaptoethanol (Invitrogen),
nonessential amino acids (Cambrex), and 10 ng/mL bFGF
(Peprotech). Cultures were maintained at 37°C, 5% CO2, with
media changes every other day. IPSCs were picked, expanded,
and characterized. For CFA experiments, plates were fixed with
50% methanol/10% acetic acid/40% water for 5 min, stained
with 0.1% Coomassie blue for 5 min, and washed with water,
and an electronically scanned photo was produced.
Immunofluorescence and AP analysis
Cells were grown on plastic coverslide chambers and fixed with
4% paraformaldehyde (PFA). The antibodies used have been de-
scribed before (Aasen et al. 2008). Rem2 antibody has been de-
scribed before (Bierings et al. 2008). Cyclin D1 was used at 1:100
(Santa Cruz Biotechnologies). The secondary antibodies used
were all the Alexa Fluor series from Invitrogen (all 1:500). Images
were taken using a Leica SP5 confocal microscope. Direct AP
activity was analyzed using an Alkaline Phosphatase Blue/Red
Membrane Substrate solution kit according to the manufac-
turer’s guidelines (Sigma).
Chemical inhibitors
Inhibitors were used at the concentration and time described in
Figure 2 or with vehicle alone. FGFr (SU5402), JNK (SP600125),
TGF-b-R1 Kinase-Alk5 (Inhibitor II), and Rho-kinase (Y-27632)
were all purchased from Calbiochem.
In vitro differentiation
Differentiation toward endoderm, mesoderm, and neuroecto-
derm was carried out by plating EBs on gelatin and DMEM
medium with 20% FCS changed every second day for 2–3 wk.
Cells were then stained for appropriate markers as described in
the figures.
Flow cytometry analyses
All analyses were performed on a MoFlo cell sorter
(DakoCytomation) running Summit software. For measuring ap-
optosis and proliferation, we used the commercial kits from
Invitrogen—the ‘‘MitoProbeDilC1(5) Assay kit’’ and the ‘‘Click-iT
EdU AlexaFluor647 Flow Cytometry Assay kit,’’ respectively—
following the manufacturer’s instructions. For the proliferation
assay using the click-IT kit, instead of using the supplied DNA
dyes, we used a homemade DNA DAPI-staining solution (0.1 M
Tris Base at pH 7.4, 0.9% or 150mMNaCl, 1 mMCaCl2, 0.5 mM
MgCl2, 0.2% BSA, 0.1% Nonidet NP-40, 10 mg/mL DAPI) at
0.5 mL per test (2 h at room temperature or overnight at 4°C).
Western blot
Western blot analyses were performed as described previously,
using extracts of cells collected by centrifugation, washed twice
in PBS, lysed in 13 lysis buffer (50 nM Tris-HCl, 70 mM
2-mercaptoethanol, 2% sodium dodecylsulfate [SDS]), then
boiled for 5 min and subjected to 12% polyacrylamide SDS gel
electrophoresis. After electrophoresis, proteins were transferred
to a nitrocellulose membrane using a submerged transfer appa-
ratus (Bio-Rad) filled with 25mMTris Base, 200mM glycine, and
20% methanol. After blocking with 5% nonfat dried milk in
TBS-T (50 mM Tris-HCl at pH 8.0, 150 mM NaCl, 0.1% Tween
20), the membrane was incubated with the primary antibodies
diluted in TBS-T and washed extensively. Primary antibodies
were anti-Flag (Sigma), BRCA-1 (Santa Cruz Biotechnologies),
p53 (Santa Cruz Biotechnologies, D01), MDM2 (4B2) (Chen et al.
1993), MDM4 (Affinity, bioreagents PA1-24307), Bax (Santa Cruz
Biotechnologies), tubulin, and cleaved Caspase 3 (Cell Signaling,
5A1). The membrane was washed three times with TBS-T and
then incubated with the appropriate horseradish peroxidase-
linked secondary antibody (Amersham). The detection was
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performed with the Western Breeze Immunodetection kit
(Invitrogen). The concentration of protein was measured by
the Bradford assay. For the ubiquitination assay for MDM4, we
used a previously described protocol (Xirodimas et al. 2001).
Briefly, hESCswere infected with ubiquitin lentivirus, and stably
expressed Ub-hESCs were then infected again with Rem2. Cells
were then treated with Mitomycin C, and the ubiquitination
assay for MDM4 was performed.
Real-time PCR
Total mRNA was isolated using Trizol and 1 mg was used to
synthesize cDNA using the Invitrogen Cloned AMV First-Strand
cDNA synthesis kit. One microliter to 2 mL of the reaction were
used to quantify gene expression by quantitative PCR for trans-
genes, endogenous pluripotent genes, as described previously
(Aasen et al. 2008). For analysis of cell cycle and apoptosis-
related genes, we used a real-time PCR superarray for human cell
cycle genes. For Rem2, MDM2, and cyclin D1, we used the
following primers: hRem2: FOR, AGATGCCACGCTACTAAA
GAAG, and REV, GCCCAAGGAGTCAGACGAGCCA; hCyclin
D1: FOR, GATCAAGTGTGACCCGGACT, and REV, TCCTC
CTCCTCTTCCTCCTC; hMDM2: FOR, TGTTGGTGCACAA
AAAGACA, and REV, CACGCCAAACAAATCTCCTA; p21:
FOR, ACCTGTCACTGTCTTGTACCCTTGT, and REV, GTTT
GGAGTGGTAGAAATCTGTCATG.
Real-time PCR superarrays for cell cycle genes were pur-
chased, and the manufacturer’s instructions were followed (SA
Biosciences).
Quantification using computer-aided analysis software
Analysis of the number of colonies in CFAs was done using
computer-assisted video analysis using Metamorph software.
Briefly, a region of interest was set in a photograph of the CFA,
a threshold for color was set (blue), and the number of colonies
was exported directly to Excel for analysis. All data were an-
alyzed using Excel spreadsheet software for mean, standard
deviation, and Student’s t-test.
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